.

Pharmaceutical Business Intelligence

  • Find generic sources and suppliers
  • Predict branded drug patent expiration
  • Uncover prior art in abandoned patent applications and expired patents

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 6,087,383

« Back to Dashboard

Which drugs does patent 6,087,383 protect, and when does it expire?

Patent 6,087,383 protects REYATAZ and EVOTAZ and is included in three NDAs. There have been three Paragraph IV challenges on Reyataz. There are four tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for REYATAZ has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-seven patent family members in thirty-six countries.

Summary for Patent: 6,087,383

Title: Bisulfate salt of HIV protease inhibitor
Abstract:The present invention provides the crystalline bisulfate salt of the formula ##STR1## which is found to have unexpectedly high solubility/dissolution rate and oral bioavailability relative to the free base form of this azapeptide HIV protease inhibitor compound.
Inventor(s): Singh; Janak (Lawrenceville, NJ), Pudipeddi; Madhusudhan (Plainsboro, NJ), Lindrud; Mark D. (Basking Ridge, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:09/217,538
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bristol Myers Squibb
REYATAZ
atazanavir sulfate
POWDER;ORAL206352-001Jun 2, 2014RXYesYes6,087,383*PED► SubscribeY
Bristol-myers Squibb
EVOTAZ
atazanavir sulfate; cobicistat
TABLET;ORAL206353-001Jan 29, 2015RXYesYes6,087,383*PED► SubscribeY
Bristol Myers Squibb
REYATAZ
atazanavir sulfate
CAPSULE;ORAL021567-001Jun 20, 2003DISCNYesNo6,087,383*PED► SubscribeY
Bristol Myers Squibb
REYATAZ
atazanavir sulfate
CAPSULE;ORAL021567-002Jun 20, 2003RXYesNo6,087,383*PED► SubscribeY
Bristol Myers Squibb
REYATAZ
atazanavir sulfate
CAPSULE;ORAL021567-003Jun 20, 2003RXYesNo6,087,383*PED► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,087,383

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovakia10622000► Subscribe
Russian Federation2186070► Subscribe
Romania118869► Subscribe
Portugal1056722► Subscribe
Poland190744► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc